AP128 Vaccine Shows Preliminary Safety in Stage IV CRC
Scott Kopetz, MD, PhD, FACP, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.
Scott Kopetz, MD, PhD, FACP, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.
The AP128 vaccine was well-tolerated as a monotherapy and in combination with the anti-PD-1 agent, ezabenlimab in patients with stage IV colorectal cancer treated in the KISIMA-01 clinical trial. Preliminary data also suggest this therapy may induce immune-mediated responses seen in the peripheral circulation and increased infiltration of TILs into liver metastases, explains Kopetz.
The KISIMA-01 study is ongoing and investigating the efficacy of the agent alone and in combination with ezabenlimab.
